The more targeted therapy in breast cancer is designed on the immunohistochemical expression of hormone receptors: human epidermal growth factor receptor positive (HER2 +), estrogen receptor positive (ER +), and progesterone receptor positive (PR +) [2]. This evidence concerns the gene ERBB2 and breast carcinoma.